Hector R Wong1, Ron W Reeder2, Russell Banks2, Robert A Berg3, Kathleen L Meert4, Mark W Hall5, Patrick S McQuillen6, Peter M Mourani7, Ranjit S Chima1, Samuel Sorenson2, James W Varni8, Julie McGalliard9, Jerry J Zimmerman9. 1. Division of Critical Care Medicine, Cincinnati Children's Hospital Medical Center, Cincinnati, OH. 2. The University of Utah, Salt Lake City, UT. 3. Children's Hospital of Philadelphia, Philadelphia, PA. 4. Children's Hospital of Detroit, Detroit, MI. 5. Nationwide Children's Hospital, Columbus, OH. 6. Benioff Children's Hospital, University of California, San Francisco, San Francisco, CA. 7. Children's Hospital of Colorado, Aurora, CO. 8. Texas A&M University, College Station, TX. 9. Seattle Children's Hospital, Seattle Children's Research Institute, University of Washington School of Medicine, Seattle, WA.
Abstract
OBJECTIVES: The Life After Pediatric Sepsis Evaluation investigation recently reported that one-third of children who survive sepsis experience significant health-related quality-of-life impairment compared with baseline at 1 year after hospitalization. Pediatric Sepsis Biomarker Risk Model is a multibiomarker tool for estimating baseline risk of mortality among children with septic shock. We determined if the Pediatric Sepsis Biomarker Risk Model biomarkers have predictive capacity for estimating the risk of hospital mortality and long-term health-related quality-of-life morbidity among children with community-acquired septic shock. DESIGN: Secondary analysis. SETTING: Twelve academic PICUs. PATIENTS: A subset of Life After Pediatric Sepsis Evaluation subjects (n = 173) with available blood samples. INTERVENTIONS: None. MEASUREMENTS AND MAIN RESULTS: Three predefined outcomes from the Life After Pediatric Sepsis Evaluation investigation were evaluated: all-cause hospital mortality (n = 173), and the composite outcome of mortality or persistent, serious deterioration of health-related quality of life (> 25% below baseline) among surviving children at 1 month (n = 125) or 3 months (n = 117). Pediatric Sepsis Biomarker Risk Model had an area under the receiver operating characteristic curve of 0.73 (95% CI, 0.59-0.87; p = 0.002) for estimating the risk of hospital mortality and was independently associated with increased odds of hospital mortality. In multivariable analyses, Pediatric Sepsis Biomarker Risk Model was not independently associated with increased odds of the composite outcome of mortality or deterioration of persistent, serious deterioration health-related quality of life greater than 25% below baseline. A new decision tree using the Pediatric Sepsis Biomarker Risk Model biomarkers had an area under the receiver operating characteristic curve of 0.87 (95% CI, 0.80-0.95) for estimating the risk of persistent, serious deterioration health-related quality of life at 3 months among children who survived septic shock. CONCLUSIONS: Pediatric Sepsis Biomarker Risk Model had modest performance for estimating hospital mortality in an external cohort of children with community-acquired septic shock. The Pediatric Sepsis Biomarker Risk Model biomarkers appear to have utility for estimating the risk of persistent, serious deterioration of health-related quality of life up to 3 months after surviving septic shock. These findings suggest an opportunity to develop a clinical tool for early assignment of risk for long-term health-related quality-of-life morbidity among children who survive septic shock.
OBJECTIVES: The Life After Pediatric Sepsis Evaluation investigation recently reported that one-third of children who survive sepsis experience significant health-related quality-of-life impairment compared with baseline at 1 year after hospitalization. Pediatric Sepsis Biomarker Risk Model is a multibiomarker tool for estimating baseline risk of mortality among children with septic shock. We determined if the Pediatric Sepsis Biomarker Risk Model biomarkers have predictive capacity for estimating the risk of hospital mortality and long-term health-related quality-of-life morbidity among children with community-acquired septic shock. DESIGN: Secondary analysis. SETTING: Twelve academic PICUs. PATIENTS: A subset of Life After Pediatric Sepsis Evaluation subjects (n = 173) with available blood samples. INTERVENTIONS: None. MEASUREMENTS AND MAIN RESULTS: Three predefined outcomes from the Life After Pediatric Sepsis Evaluation investigation were evaluated: all-cause hospital mortality (n = 173), and the composite outcome of mortality or persistent, serious deterioration of health-related quality of life (> 25% below baseline) among surviving children at 1 month (n = 125) or 3 months (n = 117). Pediatric Sepsis Biomarker Risk Model had an area under the receiver operating characteristic curve of 0.73 (95% CI, 0.59-0.87; p = 0.002) for estimating the risk of hospital mortality and was independently associated with increased odds of hospital mortality. In multivariable analyses, Pediatric Sepsis Biomarker Risk Model was not independently associated with increased odds of the composite outcome of mortality or deterioration of persistent, serious deterioration health-related quality of life greater than 25% below baseline. A new decision tree using the Pediatric Sepsis Biomarker Risk Model biomarkers had an area under the receiver operating characteristic curve of 0.87 (95% CI, 0.80-0.95) for estimating the risk of persistent, serious deterioration health-related quality of life at 3 months among children who survived septic shock. CONCLUSIONS: Pediatric Sepsis Biomarker Risk Model had modest performance for estimating hospital mortality in an external cohort of children with community-acquired septic shock. The Pediatric Sepsis Biomarker Risk Model biomarkers appear to have utility for estimating the risk of persistent, serious deterioration of health-related quality of life up to 3 months after surviving septic shock. These findings suggest an opportunity to develop a clinical tool for early assignment of risk for long-term health-related quality-of-life morbidity among children who survive septic shock.
Authors: Hector R Wong; J Timothy Caldwell; Natalie Z Cvijanovich; Scott L Weiss; Julie C Fitzgerald; Michael T Bigham; Parag N Jain; Adam Schwarz; Riad Lutfi; Jeffrey Nowak; Geoffrey L Allen; Neal J Thomas; Jocelyn R Grunwell; Torrey Baines; Michael Quasney; Bereketeab Haileselassie; Christopher J Lindsell Journal: Sci Transl Med Date: 2019-11-13 Impact factor: 17.956
Authors: Scott L Weiss; Julie C Fitzgerald; John Pappachan; Derek Wheeler; Juan C Jaramillo-Bustamante; Asma Salloo; Sunit C Singhi; Simon Erickson; Jason A Roy; Jenny L Bush; Vinay M Nadkarni; Neal J Thomas Journal: Am J Respir Crit Care Med Date: 2015-05-15 Impact factor: 21.405
Authors: Francis Leclerc; Stéphane Leteurtre; Alain Duhamel; Bruno Grandbastien; François Proulx; Alain Martinot; France Gauvin; Philippe Hubert; Jacques Lacroix Journal: Am J Respir Crit Care Med Date: 2004-10-29 Impact factor: 21.405
Authors: Stéphane Leteurtre; Alain Duhamel; Julia Salleron; Bruno Grandbastien; Jacques Lacroix; Francis Leclerc Journal: Crit Care Med Date: 2013-07 Impact factor: 7.598
Authors: François Aspesberro; Megan D Fesinmeyer; Chuan Zhou; Jerry J Zimmerman; Rita Mangione-Smith Journal: Pediatr Crit Care Med Date: 2016-06 Impact factor: 3.624
Authors: Jerry J Zimmerman; Russell Banks; Robert A Berg; Athena Zuppa; Christopher J Newth; David Wessel; Murray M Pollack; Kathleen L Meert; Mark W Hall; Michael Quasney; Anil Sapru; Joseph A Carcillo; Patrick S McQuillen; Peter M Mourani; Hector Wong; Ranjit S Chima; Richard Holubkov; Whitney Coleman; Samuel Sorenson; James W Varni; Julie McGalliard; Wren Haaland; Kathryn Whitlock; J Michael Dean; Ron W Reeder Journal: Crit Care Med Date: 2020-03 Impact factor: 7.598
Authors: Hector R Wong; Scott L Weiss; John S Giuliano; Mark S Wainwright; Natalie Z Cvijanovich; Neal J Thomas; Geoffrey L Allen; Nick Anas; Michael T Bigham; Mark Hall; Robert J Freishtat; Anita Sen; Keith Meyer; Paul A Checchia; Thomas P Shanley; Jeffrey Nowak; Michael Quasney; Arun Chopra; Julie C Fitzgerald; Rainer Gedeit; Sharon Banschbach; Eileen Beckman; Patrick Lahni; Kimberly Hart; Christopher J Lindsell Journal: PLoS One Date: 2014-01-29 Impact factor: 3.240
Authors: Amanda M McIntosh; Suhong Tong; Sara J Deakyne; Jesse A Davidson; Halden F Scott Journal: Pediatr Crit Care Med Date: 2017-08 Impact factor: 3.624
Authors: Murray M Pollack; Richard Holubkov; Tomohiko Funai; J Michael Dean; John T Berger; David L Wessel; Kathleen Meert; Robert A Berg; Christopher J L Newth; Rick E Harrison; Joseph Carcillo; Heidi Dalton; Thomas Shanley; Tammara L Jenkins; Robert Tamburro Journal: Pediatr Crit Care Med Date: 2016-01 Impact factor: 3.624
Authors: Alicia M Alcamo; Scott L Weiss; Julie C Fitzgerald; Matthew P Kirschen; Laura L Loftis; Swee Fong Tang; Neal J Thomas; Vinay M Nadkarni; Sholeen T Nett Journal: Pediatr Crit Care Med Date: 2022-05-03 Impact factor: 3.971
Authors: Colleen M Badke; Lindsey Swigart; Michael S Carroll; Debra E Weese-Mayer; L Nelson Sanchez-Pinto Journal: Front Pediatr Date: 2022-01-04 Impact factor: 3.418
Authors: Sarah A Lau-Braunhut; Audrey M Smith; Martina A Steurer; Brittany L Murray; Hendry Sawe; Michael A Matthay; Teri Reynolds; Teresa Bleakly Kortz Journal: Front Pediatr Date: 2022-01-17 Impact factor: 3.418
Authors: Christopher M Horvat; Dennis W Simon; Zachary Aldewereld; Idris Evans; Rajesh Aneja; Joseph A Carcillo Journal: J Pediatr (Rio J) Date: 2020-11-23 Impact factor: 2.990